<DOC>
	<DOCNO>NCT01141283</DOCNO>
	<brief_summary>The purpose extension phase evaluate long-term safety tolerability buprenorphine transdermal system ( BTDS ) .</brief_summary>
	<brief_title>Safety BTDS Subjects With Osteoarthritic ( OA ) Pain Hip Knee : A 6-Month Open-label Extension Phase</brief_title>
	<detailed_description>Buprenorphine synthetic opioid analgesic 25 year international clinical experience indicate safe effective variety therapeutic situation relief moderate severe pain . Transdermal system may offer advantage currently indicate oral product include ease convenience use , improve compliance , possible reduction patient care , prolong consistent delivery drug .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Subjects moderate severe osteoarthritic ( OA ) pain complete visit doubleblind phase study drug , discontinue study drug due lack therapeutic effect doubleblind phase , still complete visit doubleblind phase study drug , eligible enroll extension phase . Excluded study subject ingest &gt; 2500 mg/day acetaminophen part current stable nonopioid analgesic regimen . Subjects require longacting opioid analgesic [ twicedaily dose every ( q ) 24 hour ( h ) q12h drug ] transdermal fentanyl extension phase discontinue study . Refer core study additional inclusion/exclusion information .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Opioid</keyword>
	<keyword>Transdermal</keyword>
</DOC>